Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century

Laboratory Investigation

Volumn 93, Issue 9, 2013, Pages 970-982

  Williams, Samuel A ^a   Anderson, Wade C ^a   Santaguida, Marianne T ^a   Dylla, Scott J ^a  

^a Stemcentrx   (United States)

Author keywords

cancer stem cell; xenograft

Indexed keywords

BEVACIZUMAB; IMATINIB; SORAFENIB; TRASTUZUMAB;

ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; DRUG APPROVAL; HUMAN; NEOPLASM; NONHUMAN; PATHOLOGIST; PHENOTYPE; PHYSICIAN; PRIORITY JOURNAL; SCIENTIST; SOLID TUMOR; SURGEON; XENOGRAFT; XENOTRANSPLANTATION;

ANIMALS; HUMANS; MEDICAL ONCOLOGY; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOPLASTIC STEM CELLS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84883376614     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2013.92     Document Type: Article

References (106)

1. Huff CA, Matsui W, Smith BD, et al. The paradox of response and survival in cancer therapeutics. Blood 2006;107:431-434.
2. Huff CA, Matsui WH, Douglas Smith B, et al. Strategies to eliminate cancer stem cells: clinical implications. Eur J Cancer 2006;42: 1293-1297.
3. Cantley LC, Dalton WS, DuBois RN, et al. AACR Cancer Progress Report 2012. Clin Canc Res 2012;18(21 Suppl):S1-S100.
4. Tarver T. Cancer Facts & Figures 2012. American Cancer Society (ACS). Journal of Consumer Health on the Internet 2012;16:366-367.
5. Cancer Prevention and Early Detection Facts and Figures 2012, Atlanta, 2012.
6. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
7. Lally BE, Urbanic JJ, Blackstock AW, et al. Small cell lung cancer: have we made any progress over the last 25 years Oncologist 2007;12:1096-1104.
8. Di Marco M, Di Cicilia R, Macchini M, et al. Metastatic pancreatic cancer: is gemcitabine still the best standard treatment (Review). Oncol Rep 2010;23:1183-1192.
9. Davies JM, Goldberg RM. Treatment of metastatic colorectal cancer. Semin Oncol 2011;38:552-560.
10. Hirsch FR, Wynes MW, Gandara DR, et al. The tissue is the issue: personalized medicine for non-small cell lung cancer. Clin Cancer Res 2010;16:4909-4911.
11. Mardis ER. Genome sequencing and cancer. Curr Opin Genet Dev 2012;22:245-250.
12. Baron JA. Screening for cancer with molecular markers: progress comes with potential problems. Nat Rev Cancer 2012;12:368-371.
13. Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010;12:R68.
14. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. Feb, 5:5-23.
15. Barrett JC, Frigault MM, Hollingsworth S, et al. Are companion diagnostics useful Clin Chem 2013;59:198-201.
16. Ross JS. Cancer biomarkers, companion diagnostics and personalized oncology. Biomark Med 2011;5:277-279.
17. Chin L, Andersen JN, Futreal PA. Cancer genomics: from discovery science to personalized medicine. Nat Med 2011;17:297-303.
18. Berman DM, Bosenberg MW, Orwant RL, et al. Investigative pathology: leading the post-genomic revolution. Lab Invest. 2012;92:4-8.
19. Sleijfer S, Bogaerts J, Siu LL. Designing transformative clinical trials in the cancer genome era. J Clin Oncol 2013;31:1834-1841.
20. Stephens PJ, Tarpey PS, Davies H, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012;486: 400-404.
21. Katsios C, Papaloukas C, Tzaphlidou M, et al. Next-generation sequencing-based testing for cancer mutational landscape diversity: clinical implications Expert Rev Mol Diagn 2012;12:667-670.
22. Strausberg RL, Simpson AJ. Whole-genome cancer analysis as an approach to deeper understanding of tumour biology. Br J Cancer 2010;102:243-248.
23. Meldrum C, Doyle MA, Tothill RW. Next-generation sequencing for cancer diagnostics: a practical perspective. Clin Biochem Rev 2011; 32:177-195.
24. Biesecker LG, Burke W, Kohane I, et al. Next-generation sequencing in the clinic: are we ready Nat Rev Genet 2012;13:818-824.
25. Virchow R. Editorial. Path Anat Physiol Klin Med 1855;3:23.
26. Jin K, Teng L, Shen Y, et al. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin Transl Oncol 2010;12:473-480.
27. Julien S, Merino-Trigo A, Lacroix L, et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res 2012;18:5314-5328.
28. Reyal F, Guyader C, Decraene C, et al. Molecular profiling of patientderived breast cancer xenografts. Breast Cancer Res 2012;14:R11.
29. Tentler JJ, Tan AC, Weekes CD, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 2012;9:338-350.
30. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006;66:9339-9344.
31. O'Brien CA, Kreso A, Jamieson CH. Cancer stem cells and self-renewal. Clin Cancer Res 2010;16:3113-3120.
32. Valent P, Bonnet D, De Maria R, et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 2012; 12:767-775.
33. Tomasetti C, Vogelstein B, Parmigiani G. Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. Proc Natl Acad Sci USA. 2013;110:1999-2004.
34. Vandin F, Upfal E, Raphael BJ. De novo discovery of mutated driver pathways in cancer. Genome Res 2012;22:375-385.
35. DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol 2007;25:209-216.
36. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science 1977;197:461-463.
37. Persky B, Thomson SP, Meyskens Jr. FL, et al. Methods for evaluating the morphological and immunohistochemical properties of human tumor colonies grown in soft agar. In Vitro 1982;18:929-936.
38. Coulombel L. Identification of hematopoietic stem/progenitor cells: strength and drawbacks of functional assays. Oncogene 2004;23:7210-7222.
39. Dulbecco R. Production of Plaques in Monolayer Tissue Cultures by Single Particles of an Animal Virus. Proc Natl Acad Sci USA. 1952; 38:747-752.
40. Tveit KM, Pihl A. Do cell lines in vitro reflect the properties of the tumours of origin A study of lines derived from human melanoma xenografts. Br J Cancer 1981;44:775-786.
41. Roschke AV, Tonon G, Gehlhaus KS, et al. Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 2003;63:8634-8647.
42. Daniel VC, Marchionni L, Hierman JS, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res 2009;69: 3364-3373.
43. DeVita Jr. VT, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68:8643-8653.
44. Sawyers C. Targeted cancer therapy. Nature 2004;432:294-297.
45. Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res 2009;15:4622-4629.
46. Lin JH. Applications and limitations of genetically modified mouse models in drug discovery and development. Curr Drug Metab 2008;9:419-438.
47. Dankort D, Curley DP, Cartlidge RA, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 2009;41:544-552.
48. Combest AJ, Roberts PJ, Dillon PM, et al. Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumors. Oncologist 2012;17:1303-1316.
49. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-1791.
50. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417.
51. Giovanella BC, Vardeman DM, Williams LJ, et al. Heterotransplantation of human breast carcinomas in nude mice. Correlation between successful heterotransplants, poor prognosis and amplification of the HER-2/neu oncogene. Int J Cancer 1991;47:66-71.
52. Natali PG, Nicotra MR, Bigotti A, et al. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 1990;45:457-461.
53. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960;25:85-109.
54. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290-293.
55. Dick JE. Immune-deficient mice as models for human hematopoietic disease. Mol Genet Med 1991;1:77-115.
56. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-648.
57. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-737.
58. Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
59. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835-844.
60. Rogosin S, Sandler AB. Beyond bevacizumab: antiangiogenic agents. Clin Lung Cancer. 2012;13:326-333.
61. Mattern J, Bak M, Hahn EW, et al. Human tumor xenografts as model for drug testing. Cancer Metastasis Rev 1988;7:263-284.
62. Povlsen CO, Visfeldt J, Rygaard J, Jensen G. Growth patterns and chromosome constitutions of human malignant tumours after longterm serial transplantation in nude mice. Acta Pathol Microbiol Scand A. 1975;83:709-716.
63. Dylla SJ, Beviglia L, Park IK, et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008;3:e2428.
64. Eppert K, Takenaka K, Lechman ER, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011;17:1086-1093.
65. Quintana E, Shackleton M, Sabel MS, et al. Efficient tumour formation by single human melanoma cells. Nature 2008;456:593-598.
66. Zvibel I, Smets F, Soriano H. Anoikis: roadblock to cell transplantation Cell Transplant 2002;11:621-630.
67. Alexander CM, Puchalski J, Klos KS, et al. Separating stem cells by flow cytometry: reducing variability for solid tissues. Cell Stem Cell 2009;5:579-583.
68. Ishikawa F, Yasukawa M, Lyons B, et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood 2005;106:1565-1573.
69. Kreso A, O'Brien CA, van Galen P, et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 2013;339:543-548.
70. Sottoriva A, Spiteri I, Shibata D, et al. Single-molecule genomic data delineate patient-specific tumor profiles and cancer stem cell organization. Cancer Res 2013;73:41-49.
71. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:3983-3988.
72. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401.
73. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-111.
74. Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA. 2007;104:10158-10163.
75. O'Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-110.
76. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445: 111-115.
77. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007;1:313-323.
78. Zhang S, Balch C, Chan MW, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008;68:4311-4320.
79. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-760.
80. Diehn M, Cho RW, Lobo NA, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009;458:780-783.
81. Zhou J, Zhang Y. Cancer stem cells: models, mechanisms and implications for improved treatment. Cell Cycle 2008;7:1360-1370.
82. Lee CJ, Li C, Simeone DM. Human pancreatic cancer stem cells: implications for how we treat pancreatic cancer. Transl Oncol 2008;1:14-18.
83. Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008;26:2839-2845.
84. Morrison R, Schleicher SM, Sun Y, et al. Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol 2011;2011:941876.
85. Baccelli I, Trumpp A. The evolving concept of cancer and metastasis stem cells. J Cell Biol 2012;198:281-293.
86. Visvader JE. Cells of origin in cancer. Nature 2011;469:314-322.
87. Clarkson B, Strife A, Wisniewski D, et al. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. Leukemia 2003;17:1211-1262.
88. Eaves C, Udomsakdi C, Cashman J, et al. The biology of normal and neoplastic stem cells in CML. Leuk Lymphoma 1993;11(Suppl 1): 245-253.
89. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351:657-667.
90. Sloma I, Jiang X, Eaves AC, et al. Insights into the stem cells of chronic myeloid leukemia. Leukemia 2010;24:1823-1833.
91. Dazzi F, Hasserjian R, Gordon MY, et al. Normal and chronic phase CML hematopoietic cells repopulate NOD/SCID bone marrow with different kinetics and cell lineage representation. Hematol J. 2000;1:307-315.
92. Eisterer W, Jiang X, Christ O, et al. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia 2005;19:435-441.
93. Gibbs Jr KD, Jager A, Crespo O, et al. Decoupling of tumor-initiating activity from stable immunophenotype in HoxA9-Meis1-driven AML. Cell Stem Cell 2012;10:210-217.
94. Novelli MR, Williamson JA, Tomlinson IP, et al. Polyclonal origin of colonic adenomas in an XO/XY patient with FAP. Science 1996; 272:1187-1190.
95. Preston SL, Wong WM, Chan AO, et al. Bottom-up histogenesis of colorectal adenomas: origin in the monocryptal adenoma and initial expansion by crypt fission. Cancer Res 2003;63:3819-3825.
96. Greaves LC, Preston SL, Tadrous PJ, et al. Mitochondrial DNA mutations are established in human colonic stem cells, and mutated clones expand by crypt fission. Proc Natl Acad Sci USA. 2006;103:714-719.
97. Baker AM, Graham TA, Wright NA. Pre-tumour clones, periodic selection and clonal interference in the origin and progression of gastrointestinal cancer: potential for biomarker development. J Pathol 2013;229:502-514.
98. Schroeder T. Hematopoietic stem cell heterogeneity: subtypes, not unpredictable behavior. Cell Stem Cell 2010;6:203-207.
99. Furth J, Kahn M. The transmission of leukemia of mice with a single cell. Am J Cancer 1937;31:276-282.
100. Makino S. Further evidence favoring the concept of the stem cell in ascites tumors of rats. Ann N Y Acad Sci 1956;63:818-830.
101. Hewitt H. Studies of the dissemination and quantitative transplantation of a lymphocytic leukemia of CBA mice. Br J Cancer 1958;12:378-401.
102. Bruce W, Van Der Gaag H. A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature 1963;199:79-80.
103. Southam C, Brunschwig A, Dizon Q. Autologous and homologous transplantation of human cancer. In: Brennan M, Simpson W eds. Biological Interactions in Normal and Neoplastic Growth: A Contribution to the Tumor-Host Problem. 9, Boston, MA, USA, 1962, p723-738.
104. Bailar 3rd JC, Mellinger GT, Gleason DF. Survival rates of patients with prostatic cancer, tumor stage, and differentiation-preliminary report. Cancer Chemother Rep 1966;50:129-136.
105. Li T, Su Y, Mei Y, et al. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Invest 2010;90:234-244.
106. Thunnissen E, Kerr KM, Herth FJ, et al. The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer 2012;76:1-18.